On the afternoon of October 14, 2025, Zhejiang Tianyuan Biotechnology Co., Ltd. and Ningbo Xilin Health Management Co., Ltd. formally signed an agency agreement, establishing an in-depth collaborative relationship. The signing ceremony was attended by General Manager Jiao Mingming and his team from Tianyuan Bio, alongside Lou Yijun, Founder of Ningbo Xilin Health Management Co., Ltd.

Tianyuan Bio will provide Xilin Health Management Co., Ltd. with professional and high-quality product services, jointly promoting the development of the health management industry in the Ningbo region. Meanwhile, through close collaboration with Xilin Health Management Co., Ltd., Tianyuan Bio will leverage its local market resources and customer network to further expand its business coverage, enhance brand awareness, and increase market share.

During the signing ceremony, He Jianbin, Manager of the Business Department, elaborated on the company's agency cooperation policies, while Dr. Liu Guangcheng, Director of the Cell Laboratory, shared the company's cutting-edge research achievements and demonstrated its technological advantages. General Manager Jiao Mingming stated, "We are delighted to partner with Xilin Health Management Co., Ltd. We believe that through our joint efforts, we can bring more advanced health management solutions to the residents of Ningbo." Lou Yijun also expressed, "Xilin Health has always been focused on the development of cutting-edge health technologies. The collaboration with Tianyuan Bio is a crucial step in our strategic layout. We look forward to working hand in hand with Tianyuan Bio to pioneer a new chapter in health management."

In the future, the two parties will actively explore innovative models in the field of health management through resource sharing and complementary strengths, providing customers with more comprehensive and high-quality health services. This partnership not only marks a new starting point for both companies' development but will also inject fresh vitality into the health industry in the Ningbo region.

Zhejiang Tianyuan Biotechnology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to cell research, development, production, operation, and service. It possesses valuable resource banks including an HLA Umbilical Cord Matching Library, iPS Seed Cell Bank, and Cancer Cell Bank. The company is the drafting unit for the National Health Commission's association standard on immune function assessment methods. In collaboration with the National Health Commission's Research Institute, it has co-established a Joint Laboratory for Metabolic Immunity Monitoring. Furthermore, it serves as important research and service platforms, including the Ningbo Storage Center of the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center of the National Health Commission's Research Institute.